Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 156

1.

Clinical Course of Multiple Sclerosis.

Klineova S, Lublin FD.

Cold Spring Harb Perspect Med. 2018 Jan 22. pii: a028928. doi: 10.1101/cshperspect.a028928. [Epub ahead of print]

PMID:
29358317
2.

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA.

Lancet Neurol. 2018 Feb;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. Epub 2017 Dec 21. Review.

PMID:
29275977
3.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

PMID:
29141831
4.

A composite measure to explore visual disability in primary progressive multiple sclerosis.

Poretto V, Petracca M, Saiote C, Mormina E, Howard J, Miller A, Lublin FD, Inglese M.

Mult Scler J Exp Transl Clin. 2017 May 18;3(2):2055217317709620. doi: 10.1177/2055217317709620. eCollection 2017 Apr-Jun.

5.

Relationship between timed 25-foot walk and diffusion tensor imaging in multiple sclerosis.

Klineova S, Farber R, Saiote C, Farrell C, Delman BN, Tanenbaum LN, Friedman J, Inglese M, Lublin FD, Krieger S.

Mult Scler J Exp Transl Clin. 2016 Jun 23;2:2055217316655365. doi: 10.1177/2055217316655365. eCollection 2016 Jan-Dec.

6.

Relapses in multiple sclerosis: Relationship to disability.

Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E.

Mult Scler Relat Disord. 2016 Mar;6:10-20. doi: 10.1016/j.msard.2015.09.002. Epub 2015 Sep 8. Review.

PMID:
27063617
7.

William Austin Sibley, MD (1925-2015).

Reingold SC, Lublin FD.

Mult Scler. 2016 Jan;22(1):11-2. doi: 10.1177/1352458515616206. Epub 2015 Nov 16. No abstract available.

PMID:
26573143
8.

Effect of in-painting on cortical thickness measurements in multiple sclerosis: A large cohort study.

Govindarajan KA, Datta S, Hasan KM, Choi S, Rahbar MH, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston; CombiRx Investigators Group.

Hum Brain Mapp. 2015 Oct;36(10):3749-3760. doi: 10.1002/hbm.22875. Epub 2015 Jun 19.

9.

Author response.

Lublin FD.

Neurology. 2015 Mar 3;84(9):963. No abstract available.

PMID:
25905117
10.

Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.

Lublin FD, Cutter G, Giovannoni G, Pace A, Campbell NR, Belachew S.

Mult Scler Relat Disord. 2014 Nov;3(6):705-11. doi: 10.1016/j.msard.2014.08.005. Epub 2014 Sep 6.

11.

Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study.

Lublin FD, Bowen JD, Huddlestone J, Kremenchutzky M, Carpenter A, Corboy JR, Freedman MS, Krupp L, Paulo C, Hariri RJ, Fischkoff SA.

Mult Scler Relat Disord. 2014 Nov;3(6):696-704. doi: 10.1016/j.msard.2014.08.002. Epub 2014 Aug 29.

12.

Regional gray matter atrophy in relapsing remitting multiple sclerosis: baseline analysis of multi-center data.

Datta S, Staewen TD, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS, Narayana PA; MRI Analysis Center at Houston; CombiRx Investigators Group.

Mult Scler Relat Disord. 2015 Mar;4(2):124-36. doi: 10.1016/j.msard.2015.01.004. Epub 2015 Jan 17.

13.

Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis.

Weisfeld-Adams JD, Katz Sand IB, Honce JM, Lublin FD.

Brain. 2015 Mar;138(Pt 3):517-39. doi: 10.1093/brain/awu397. Epub 2015 Jan 29. Review.

14.

Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.

Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR 3rd, Blight AR; MS-F203, MS-F204, and Extension Study Investigators.

Mult Scler. 2015 Sep;21(10):1322-31. doi: 10.1177/1352458514563591. Epub 2015 Jan 12.

15.

New multiple sclerosis phenotypic classification.

Lublin FD.

Eur Neurol. 2014;72 Suppl 1:1-5. doi: 10.1159/000367614. Epub 2014 Sep 26.

16.

Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics.

Vidaurre OG, Haines JD, Katz Sand I, Adula KP, Huynh JL, McGraw CA, Zhang F, Varghese M, Sotirchos E, Bhargava P, Bandaru VV, Pasinetti G, Zhang W, Inglese M, Calabresi PA, Wu G, Miller AE, Haughey NJ, Lublin FD, Casaccia P.

Brain. 2014 Aug;137(Pt 8):2271-86. doi: 10.1093/brain/awu139. Epub 2014 Jun 3. Erratum in: Brain. 2015 Jul;138(Pt 7):e367.

17.

Defining the clinical course of multiple sclerosis: the 2013 revisions.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B Jr, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O'Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH.

Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.

18.

Recruitment of participants to a multiple sclerosis trial: the CombiRx experience.

Bhanushali MJ, Gustafson T, Powell S, Conwit RA, Wolinsky JS, Cutter GR, Lublin FD, Cofield SS.

Clin Trials. 2014 Apr;11(2):159-66. doi: 10.1177/1740774513517184.

19.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.

Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.

PMID:
24685276
20.

Future treatment approaches to multiple sclerosis.

Derwenskus J, Lublin FD.

Handb Clin Neurol. 2014;122:563-77. doi: 10.1016/B978-0-444-52001-2.00024-8. Review.

PMID:
24507535
21.

Clinical course in multiple sclerosis patients presenting with a history of progressive disease.

Pandey KS, Krieger SC, Farrell C, Hannigan C, DeAngelis T, Miller AE, Lublin FD.

Mult Scler Relat Disord. 2014 Jan;3(1):67-71. doi: 10.1016/j.msard.2013.05.004. Epub 2013 Jul 19.

PMID:
25877975
22.

Diagnosis and differential diagnosis of multiple sclerosis.

Katz Sand IB, Lublin FD.

Continuum (Minneap Minn). 2013 Aug;19(4 Multiple Sclerosis):922-43. doi: 10.1212/01.CON.0000433290.15468.21. Review.

PMID:
23917094
23.

Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.

O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L.

J Neurol. 2013 Oct;260(10):2472-80. doi: 10.1007/s00415-013-6979-y. Epub 2013 Jul 14.

24.

MS as a gateway disease.

Lublin FD.

J Neurol Sci. 2013 Oct 15;333(1-2):73-5. doi: 10.1016/j.jns.2013.02.014. Epub 2013 Apr 8.

PMID:
23578792
25.

Atypical Chédiak-Higashi syndrome with attenuated phenotype: three adult siblings homozygous for a novel LYST deletion and with neurodegenerative disease.

Weisfeld-Adams JD, Mehta L, Rucker JC, Dembitzer FR, Szporn A, Lublin FD, Introne WJ, Bhambhani V, Chicka MC, Cho C.

Orphanet J Rare Dis. 2013 Mar 22;8:46. doi: 10.1186/1750-1172-8-46.

26.

Randomized study combining interferon and glatiramer acetate in multiple sclerosis.

Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS; CombiRx Investigators.

Ann Neurol. 2013 Mar;73(3):327-40. doi: 10.1002/ana.23863. Epub 2013 Mar 11.

27.

Interferon beta and glatiramer acetate therapy.

McGraw CA, Lublin FD.

Neurotherapeutics. 2013 Jan;10(1):2-18. doi: 10.1007/s13311-012-0163-4. Review.

28.

Use of Magnetic Resonance Imaging as Well as Clinical Disease Activity in the Clinical Classification of Multiple Sclerosis and Assessment of Its Course: A Report from an International CMSC Consensus Conference, March 5-7, 2010.

Cook SD, Dhib-Jalbut S, Dowling P, Durelli L, Ford C, Giovannoni G, Halper J, Harris C, Herbert J, Li D, Lincoln JA, Lisak R, Lublin FD, Lucchinetti CF, Moore W, Naismith RT, Oehninger C, Simon J, Sormani MP.

Int J MS Care. 2012 Fall;14(3):105-14. doi: 10.7224/1537-2073-14.3.105.

29.

The CombiRx trial of combined therapy with interferon and glatiramer cetate in relapsing remitting MS: Design and baseline characteristics.

Lindsey J, Scott T, Lynch S, Cofield S, Nelson F, Conwit R, Gustafson T, Cutter G, Wolinsky J, Lublin F; the CombiRx Investigators Group.

Mult Scler Relat Disord. 2012 Apr 1;1(2):81-86. Epub 2012 Feb 23.

30.

Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects.

Cohen JA, Reingold SC, Polman CH, Wolinsky JS; International Advisory Committee on Clinical Trials in Multiple Sclerosis.

Lancet Neurol. 2012 May;11(5):467-76. doi: 10.1016/S1474-4422(12)70059-5. Review.

PMID:
22516081
31.

The CombiRx trial of combined therapy with interferon and glatiramer acetate in relapsing remitting MS: Design and baseline characteristics.

Lindsey JW, Scott TF, Lynch SG, Cofield SS, Nelson F, Conwit R, Gustafson T, Cutter GR, Wolinsky JS, Lublin FD; CombiRx Investigators Group.

Mult Scler Relat Disord. 2012 Apr;1(2):81-6. doi: 10.1016/j.msard.2012.01.006. Epub 2012 Feb 23.

PMID:
25876935
32.

Disease activity free status in MS.

Lublin FD.

Mult Scler Relat Disord. 2012 Jan;1(1):6-7. doi: 10.1016/j.msard.2011.08.001. Epub 2011 Aug 27. No abstract available.

PMID:
25876444
33.

Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study.

Narayana PA, Govindarajan KA, Goel P, Datta S, Lincoln JA, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS; MRI Analysis Center at Houston; The CombiRx Investigators Group.

Neuroimage Clin. 2012 Nov 30;2:120-31. doi: 10.1016/j.nicl.2012.11.009. eCollection 2012.

34.

Relapses do not matter in relation to long-term disability: no (they do).

Lublin FD.

Mult Scler. 2011 Dec;17(12):1415-6. doi: 10.1177/1352458511427515. No abstract available.

PMID:
22130598
35.

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.

O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N.

Neurology. 2011 May 31;76(22):1858-65. doi: 10.1212/WNL.0b013e31821e7c8a. Epub 2011 May 4.

PMID:
21543733
36.

Treatment of multiple sclerosis exacerbations.

Repovic P, Lublin FD.

Neurol Clin. 2011 May;29(2):389-400. doi: 10.1016/j.ncl.2010.12.012.

PMID:
21439448
37.

Multiple sclerosis as a model neurologic disease.

Lublin FD, DeAngelis TM.

Mt Sinai J Med. 2011 Mar-Apr;78(2):159-60. doi: 10.1002/msj.20238. No abstract available.

PMID:
21425261
38.

Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.

Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE.

Mult Scler. 2011 Aug;17(8):970-9. doi: 10.1177/1352458511399611. Epub 2011 Mar 18.

PMID:
21421809
39.

Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS.

Ann Neurol. 2011 Feb;69(2):292-302. doi: 10.1002/ana.22366.

40.

Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis.

Lünemann A, Tackenberg B, DeAngelis T, da Silva RB, Messmer B, Vanoaica LD, Miller A, Apatoff B, Lublin FD, Lünemann JD, Münz C.

Int Immunol. 2011 Feb;23(2):139-48. doi: 10.1093/intimm/dxq463. Epub 2011 Jan 6.

41.

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R, Marinucci LN, Blight AR; MSF204 Investigators.

Ann Neurol. 2010 Oct;68(4):494-502. doi: 10.1002/ana.22240.

PMID:
20976768
42.

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks.

Morrow SA, O'Connor PW, Polman CH, Goodman AD, Kappos L, Lublin FD, Rudick RA, Jurgensen S, Paes D, Forrestal F, Benedict RH.

Mult Scler. 2010 Nov;16(11):1385-92. doi: 10.1177/1352458510378021. Epub 2010 Aug 25.

PMID:
20739335
43.

Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.

Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW; SENTINEL Investigators.

J Neurol Sci. 2010 May 15;292(1-2):28-35. doi: 10.1016/j.jns.2010.02.012. Epub 2010 Mar 16.

PMID:
20236661
44.

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial.

Engel WK.

Neurology. 2009 Sep 29;73(13):1077; author reply 1077-8. doi: 10.1212/WNL.0b013e3181ab6b81. No abstract available.

PMID:
19786702
45.

Assessing disability progression with the Multiple Sclerosis Functional Composite.

Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW.

Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212.

PMID:
19667023
46.

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.

Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM.

Neurology. 2009 Jun 9;72(23):1989-93. doi: 10.1212/WNL.0b013e3181a92b96.

47.

Proof of concept studies for tissue-protective agents in multiple sclerosis.

Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ, Calabresi PA, Cohen JA, Cole PE, Glanzman R, Goelz S, Inglese M, Kapoor R, Kappos L, Kreitman R, Lublin FD, Mann A, Marrie RA, O'Looney P, Polman CH, Ravina BM, Reingold SC, Richert JR, Sandrock AW, Waubant E.

Mult Scler. 2009 May;15(5):542-6. doi: 10.1177/1352458508101939. Review.

PMID:
19389749
48.

Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal.

Pandey K, Lublin FD.

Curr Treat Options Neurol. 2009 May;11(3):193-202.

PMID:
19364454
49.

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA; AFFIRM and SENTINEL Investigators.

J Neurol. 2009 Mar;256(3):405-15. doi: 10.1007/s00415-009-0093-1. Epub 2009 Mar 18. Erratum in: J Neurol. 2009 Jun;256(6):1035-7.

PMID:
19308305
50.

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R, Marinucci LN, Blight AR; Fampridine MS-F203 Investigators.

Lancet. 2009 Feb 28;373(9665):732-8. doi: 10.1016/S0140-6736(09)60442-6.

PMID:
19249634

Supplemental Content

Loading ...
Support Center